[Platelet melatonin levels in healthy donors].

A convenient and reliable enzyme immunoassay of platelet melatonin has been developed using the Melatonin ELISA kits (IBL Hamburg GmBH). The proposed methods permit the quantitative determination of platelet melatonin, which opens up new prospects for using this indicator for diagnostic purposes.

[Melatonin expression in nasal polyps in patients with asthmatic triad].

The expression of melatonin in nasal polyps versus the histological structure of tissue was studied in 11 patients with aspirin-induced asthma (AIA), 8 patients with asthma without aspirin intolerance, 13 patients with polypous rhinosinusopathy (PR) without bronchopulmonary diseases, and 10 apparently healthy individuals without nasal polyposis. The expression of melatonin in the nasal mucosa was found to be normal in healthy individuals. It significantly increased in polyp tissue in PR.

[Melatonin production in thrombocytes and their functional activity in patients with aspirin asthma].

The aim of the investigation was to study melatonin production in thrombocytes and their functional activity in correlation with 6-sulfatoximelatonin (6-SOM) urinary excretion in patients with aspirin-induced bronchial asthma (AIBA). Forty-three patients with bronchial asthma (BA) were examined. The main group consisted of 26 AIBA patients; the comparison group consisted of 17 BA patients with no intolerance to aspirin or other non-steroidal anti-inflammatory drugs; 30 practically healthy individuals constituted the control group.

[Results of Befnorin clinical trails in healthy volunteers].

Clinical trails of Befnorin based on the human recombinant TNF-beta elaborated at the Research Design and Technology Institute of Biologically Active Substances, "Vector" State Research Center of Virology and Biotechnology, were carried out on healthy volunteers in compliance with a decision passed by the Committee of Medical and Immunobiological Preparations, Russia's Health Ministry. Single Befnorin doses of 5-10(4) U, 10(5) U, 5-10(5) U, and 10(6) U were administered as intramuscular injections. Clinical, biochemical and immunological parameters were registered for 7 days after a single dose.